New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
08:37 EDTBIOCBiocept expands breast cancer offering
Biocept announced the launch of its estrogen receptor status testing on CTCs that will be performed at the Company's CLIA-certified and CAP-accredited laboratory. The launch of ER status testing, in conjunction with the company's HER2 receptor status test, will offer health care providers an additional testing option when a tumor biopsy is unavailable or unsafe. For patients with recurring or newly diagnosed metastatic breast cancer, accurate identification of hormone and HER2 receptors status plays a major role in treatment outcomes. The company said, "Our validation study for hormone status provided significant insights into hormone status as it relates to primary and metastatic breast cancers. We were able to correlate both concordance and discordance of primary biopsy tissue and metastatic biopsy tissue with the CTC status of estrogen receptors."
News For BIOC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 13, 2015
16:51 EDTBIOCBiocept files $50M mixes securities shelf
Subscribe for More Information
09:21 EDTBIOCOn The Fly: Pre-market Movers
Subscribe for More Information
May 12, 2015
17:09 EDTBIOCBiocept reports Q1 EPS (37c) vs. ($1.96) last year
Subscribe for More Information
May 11, 2015
10:28 EDTBIOCLiquid biopsies may 'transform' cancer treatment, AP says
As more people get liquid biopsies to guide treatment, Associated Press said the tests have the potential to "transform cancer treatment." Biocept, which is not mentioned by name in the story, is a cancer diagnostics company developing circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample. Shares of the small-cap stock are up nearly 5% in early trading. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use